DC excipient

Abstract Aims: Different types of drug release modifying polymers, their grades and quantities have to be optimised in the formulation considering...

Abstract Objectives: The current study presents a sequential strategy for the development of directly compressible powder formulations relying on Design...

Abstract Purpose This research was designed to systematically investigate the performance of three lactose-based co-processed excipients (CPEs): SuperTab® 40LL, StarLac®, and...

Abstract Bulk density (ρb) serves as a fundamental powder parameter across various industries. In the pharmaceutical industry, its implications on...

Abstract Background: Pantoprazole is a widely used proton pump inhibitor that is highly unstable under acidic conditions. This limits the performance...

Abstract Successful development of direct-compression formulations can be hindered by poor compactibility of active pharmaceutical ingredients active pharmaceutical ingredients (APIs),...

Abstract Background/Objectives: The development of extended-release oral dosage forms remains a complicated and time consuming process, particularly during early formulation...

Abstract Minitablets are an innovative dosage form with a diameter of ≤ 3 mm that offer solutions for many unmet needs in...

Formulation Challenges in Low-Dose Fixed-Dose Combinations Developing fixed-dose combination (FDC) therapies presents unique formulation challenges, particularly when one active pharmaceutical...

Abstract Excipients are indispensable components of pharmaceutical dosage forms, significantly influencing product quality, safety, and performance. Conventional single excipients often...